These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 22053899)

  • 1. Comparison of pretargeted and conventional CC49 radioimmunotherapy using 149Pm, 166Ho, and 177Lu.
    Mohsin H; Jia F; Bryan JN; Sivaguru G; Cutler CS; Ketring AR; Miller WH; Simón J; Frank RK; Theodore LJ; Axworthy DB; Jurisson SS; Lewis MR
    Bioconjug Chem; 2011 Dec; 22(12):2444-52. PubMed ID: 22053899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice.
    Lewis MR; Zhang J; Jia F; Owen NK; Cutler CS; Embree MF; Schultz J; Theodore LJ; Ketring AR; Jurisson SS; Axworthy DB
    Nucl Med Biol; 2004 Feb; 31(2):213-23. PubMed ID: 15013487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
    Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
    Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
    Shen S; Forero A; LoBuglio AF; Breitz H; Khazaeli MB; Fisher DR; Wang W; Meredith RF
    J Nucl Med; 2005 Apr; 46(4):642-51. PubMed ID: 15809487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein.
    Sato N; Hassan R; Axworthy DB; Wong KJ; Yu S; Theodore LJ; Lin Y; Park L; Brechbiel MW; Pastan I; Paik CH; Carrasquillo JA
    J Nucl Med; 2005 Jul; 46(7):1201-9. PubMed ID: 16000290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
    Su FM; Beaumier P; Axworthy D; Atcher R; Fritzberg A
    Nucl Med Biol; 2005 Oct; 32(7):741-7. PubMed ID: 16243650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiolanthanide-labeled monoclonal antibody CC49 for radioimmunotherapy of cancer: biological comparison of DOTA conjugates and 149Pm, 166Ho, and 177Lu.
    Mohsin H; Jia F; Sivaguru G; Hudson MJ; Shelton TD; Hoffman TJ; Cutler CS; Ketring AR; Athey PS; Simón J; Frank RK; Jurisson SS; Lewis MR
    Bioconjug Chem; 2006; 17(2):485-92. PubMed ID: 16536481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.
    Knox SJ; Goris ML; Tempero M; Weiden PL; Gentner L; Breitz H; Adams GP; Axworthy D; Gaffigan S; Bryan K; Fisher DR; Colcher D; Horak ID; Weiner LM
    Clin Cancer Res; 2000 Feb; 6(2):406-14. PubMed ID: 10690517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
    Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
    J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
    Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
    J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
    Buchsbaum D; Khazaeli MB; Liu T; Bright S; Richardson K; Jones M; Meredith R
    Cancer Res; 1995 Dec; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using streptavidin-CC49 monoclonal antibody and 90Y-DOTA-biotin.
    Domingo RJ; Reilly RM
    Nucl Med Commun; 2000 Jan; 21(1):89-96. PubMed ID: 10717908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trans-cyclooctene tag with improved properties for tumor pretargeting with the diels-alder reaction.
    Rossin R; van Duijnhoven SM; Läppchen T; van den Bosch SM; Robillard MS
    Mol Pharm; 2014 Sep; 11(9):3090-6. PubMed ID: 25077373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-Dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs.
    Goel A; Augustine S; Baranowska-Kortylewicz J; Colcher D; Booth BJ; Pavlinkova G; Tempero M; Batra SK
    Clin Cancer Res; 2001 Jan; 7(1):175-84. PubMed ID: 11205906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies.
    Lin Y; Pagel JM; Axworthy D; Pantelias A; Hedin N; Press OW
    Cancer Res; 2006 Apr; 66(7):3884-92. PubMed ID: 16585217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma.
    Hamblett KJ; Press OW; Meyer DL; Hamlin DK; Axworthy D; Wilbur DS; Stayton PS
    Bioconjug Chem; 2005; 16(1):131-8. PubMed ID: 15656584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
    Yao Z; Zhang M; Axworthy DB; Wong KJ; Garmestani K; Park L; Park CW; Mallett RW; Theodore LJ; Yau EK; Waldmann TA; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
    Cancer Res; 2002 Oct; 62(20):5755-60. PubMed ID: 12384535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting strategies for cancer radiotherapy.
    Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system.
    Goodwin DA; Meares CF; Osen M
    J Nucl Med; 1998 Oct; 39(10):1813-8. PubMed ID: 9776294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.